In the prospective study for the use of Tinospora rumphii Boerl (Makabuhay) against scabies, 91 institutionalized children were employed. Five were dropouts. Only those with mild to moderate ectoparasitic scabies infection were included. The standard treatment of choice used in the comparative study was Crotamiton (Eurax) because it is less toxic than other scabicidal drugs. The subjects were treated for three days and observed fo three to 13 days. Of the 86 subjects treated, three were unresponsive to T. romphii Boerl and four for Eurax. Our study shows that both modes of medications are equally effective.